Immatics (IMTX) to Release Quarterly Earnings on Tuesday

Immatics (NASDAQ:IMTX - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Immatics to post earnings of ($0.39) per share and revenue of $14.92 million for the quarter.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.51. The company had revenue of $15.67 million during the quarter, compared to analyst estimates of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. On average, analysts expect Immatics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immatics Stock Down 3.5 %

IMTX stock traded down $0.18 during midday trading on Tuesday, reaching $4.92. 108,859 shares of the company's stock traded hands, compared to its average volume of 652,335. The company has a 50-day simple moving average of $4.48 and a two-hundred day simple moving average of $6.13. Immatics has a 1-year low of $3.30 and a 1-year high of $13.77. The company has a market cap of $598.03 million, a price-to-earnings ratio of -7.48 and a beta of 0.87.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an "overweight" rating on shares of Immatics in a report on Tuesday, April 1st. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $16.67.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Immatics stock. Bank of America Corp DE grew its position in Immatics (NASDAQ:IMTX - Free Report) by 166.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,575 shares of the company's stock after purchasing an additional 2,231 shares during the period. Bank of America Corp DE's holdings in Immatics were worth $25,000 at the end of the most recent reporting period. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.